Oral Semaglutide Tablets

Semaglutide is currently available in India through branded products: the oral tablet version under Rybelsus (for type 2 diabetes) and the injectable version under Wegovy (for obesity/weight-management) launched in June 2025. 

The core patents on semaglutide in India are expected to expire around March 2026. 

Many Indian generic/pharma companies (e.g., Dr Reddy’s Laboratories, Cipla, Sun Pharma, Biocon) are preparing for generic semaglutide launches. 

Price expectations: With generics coming, analysts expect big price drops compared to current branded versions (which are expensive) in India.

If you’re watching for affordable semaglutide options in India: expect that generics should start appearing in 2026 or later, once patent barriers clear.

Cost reduction: With generics, there is a strong possibility of drastic price drops (analysts mention maybe 60-90% cheaper) compared to existing branded versions. 

Formulation differences: The oral version (tablet) is somewhat different clinically compared to injectable forms (dose, absorption, weight-loss effect). So generic oral availability is somewhat different from injectables.

Regulatory & quality caution: As with all generics, ensure that any product is approved and meets quality standards (in India, via Central Drugs Standard Control Organisation (CDSCO) and other regulatory oversight).